NCT00734630
Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients
See it on ClinicalTrials.gov ↗491 people
39.9%
60.1%
196 womenmiddle line = equal numbers295 men
- Phase
- PHASE4
- Paid for by
- Forest Laboratories
- Finished
- 2010-05
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – 85 Years
- Average age
- mean 52.9 years
- Age 65+
- 12.4%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Severe hypertension, including chronic kidney disease”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Documented congestive heart failure”
Study titles and rules are shown in their original English.